CRYOPORT, INC. Cost, Depreciation, Amortization and Depletion
CRYOPORT, INC. (CYRX) reported Cost, Depreciation, Amortization and Depletion of $2.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostDepreciationAmortizationAndDepletion · last filed 2026-08-06
- CRYOPORT, INC. cost, depreciation, amortization and depletion for the quarter ending 2026-06-30 was $2.40M, a 14.29% increase year-over-year.
- CRYOPORT, INC. cost, depreciation, amortization and depletion for the quarter ending 2026-03-31 was $2.20M, a 10.00% increase year-over-year.
- CRYOPORT, INC. cost, depreciation, amortization and depletion for the quarter ending 2025-12-31 was $2.00M, a 0.00% change year-over-year.
- CRYOPORT, INC. cost, depreciation, amortization and depletion for the quarter ending 2025-09-30 was $2.10M, a 10.53% increase year-over-year.
- CRYOPORT, INC. cost, depreciation, amortization and depletion for fiscal 2025 was $8.20M, a 7.89% increase from fiscal 2024.
- CRYOPORT, INC. cost, depreciation, amortization and depletion for fiscal 2024 was $7.60M, a 18.75% increase from fiscal 2023.
- CRYOPORT, INC. cost, depreciation, amortization and depletion for fiscal 2023 was $6.40M.
| Period end | Cost, Depreciation, Amortization and Depletion 3 month | Cost, Depreciation, Amortization and Depletion 6 month | Cost, Depreciation, Amortization and Depletion 9 month | Cost, Depreciation, Amortization and Depletion 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.40M 10-Q · filed 2026-08-06 | $4.60M 10-Q · filed 2026-08-06 | $6.60M derived: sum of 3 quarters · filed 2026-08-06 | $8.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.20M 10-Q · filed 2026-05-05 | $4.20M derived: sum of 2 quarters · filed 2026-05-05 | $6.30M derived: sum of 3 quarters · filed 2026-05-05 | $8.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $4.10M derived: sum of 2 quarters · filed 2026-03-05 | $6.20M derived: sum of 3 quarters · filed 2026-08-06 | $8.20M 10-K · filed 2026-03-05 |
| 2025-09-30 | $2.10M 10-Q · filed 2025-11-06 | $4.20M derived: sum of 2 quarters · filed 2026-08-06 | $6.20M 10-Q · filed 2025-11-06 | $8.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.10M 10-Q · filed 2026-08-06 | $4.10M 10-Q · filed 2026-08-06 | $6.10M derived: sum of 3 quarters · filed 2026-08-06 | $8.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.00M 10-Q · filed 2026-05-05 | $4.00M derived: sum of 2 quarters · filed 2026-05-05 | $5.90M derived: sum of 3 quarters · filed 2026-05-05 | |
| 2024-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.90M derived: sum of 2 quarters · filed 2026-03-05 | $7.60M 10-K · filed 2026-03-05 | |
| 2024-09-30 | $1.90M 10-Q · filed 2025-11-06 | $5.60M 10-Q · filed 2025-11-06 | ||
| 2023-12-31 | $6.40M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |